Clinical trial · Interventional
Neurocognitive Function After Prophylactic Cranial Irradiation & Hippocampal Sparing in LD SCLC Patients - a Pilot Study
Neurocognitive Function Changes in Patients With LD Small Cell Lung Cancer Undergoing Prophylactic Whole Brain Radiotherapy With Hippocampal Sparing - a Pilot Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Small cell lung cancer (SCLC) harbors a high risk for brain metastases. Prophylactic whole brain radiotherapy (PCI)) is the standard treatment for these patients after completing chemo-radiotherapy to the chest, with a 5% survival advantage. Recent data suggest minimal risk for hippocampal involvement in these patients. There is no published data thus far testing the effect of hippocampal sparing during WBRT on the patient's neuro-cognitive function, QOL, and survival.., The goals of the proposed study are to assess prospectively the neurocognitive changes in patients with LD SCLC who are candidates for PCI before, and periodically after PCI
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Small Cell | Small Cell Neuroendocrine Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Whole brain radiotherapy with reduced dose to the hippocampi | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Pilot group
- description
- Five eligible patients will undergo WBRT with reduced dose to the hippocampi and will be evaluated prospectively by neuro cognitive testing, MRI scans and blood tests.
- interventionNames
- Radiation: Whole brain radiotherapy with reduced dose to the hippocampi
Primary outcomes (1)
- measure
- Number of patients that complete a year of imaging, neuro-cognitive and clinical follow up after WBRT with HC sparing as a measure of feasibility to conduct a randomized study in this patient population.
- timeFrame
- 1 year
Secondary outcomes (3)
- measure
- Number of patients with no changes in the neurocognitive tests score and QOL as a measure for the correlation between NCT and HC sparing.
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients with histologically confirmed LD SCLC and complete response (CR) of the primary lesion after chemo-radiotherapy to the chest and who are candidates for PCI will be accrued Exclusion Criteria: * A history of malignant disease other then SCLC * Previous cranial irradiation * Medical or social condition which limits the ability of the patient to undergo neuro-cognitive testing
References
Publications (0)
Data not yet available